| Field | Row 1 |
|---|---|
| adsh | 0001396814-25-000061 |
| cik | 1396814 |
| name | PACIRA BIOSCIENCES, INC. |
| sic | 2834 |
| countryba | US |
| stprba | CA |
| cityba | BRISBANE |
| zipba | 94005 |
| bas1 | 2000 SIERRA POINT PARKWAY |
| bas2 | SUITE 900 |
| baph | 650-242-8052 |
| countryma | US |
| stprma | CA |
| cityma | BRISBANE |
| zipma | 94005 |
| mas1 | 2000 SIERRA POINT PARKWAY |
| mas2 | SUITE 900 |
| countryinc | US |
| stprinc | DE |
| ein | 510619477 |
| former | PACIRA PHARMACEUTICALS, INC. |
| changed | 20101029 |
| afs | 1-LAF |
| wksi | 0 |
| fye | 1231 |
| form | 10-Q |
| period | 20250331 |
| fy | 2025 |
| fp | Q1 |
| filed | 20250508 |
| accepted | 2025-05-08 16:07:00.0 |
| prevrpt | 0 |
| detail | 1 |
| instance | pcrx-20250331_htm.xml |
| nciks | 1 |
| aciks |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| cik | Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings. |
| name | Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date. |
| sic | Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business. |
| countryba | The ISO 3166-1 country of the registrant's business address. |
| stprba | The state or province of the registrant’s business address, if field countryba is US or CA. |
| cityba | The city of the registrant's business address. |
| zipba | The zip code of the registrant’s business address. |
| bas1 | The first line of the street of the registrant’s business address. |
| bas2 | The second line of the street of the registrant’s business address. |
| baph | The phone number of the registrant’s business address. |
| countryma | The ISO 3166-1 country of the registrant's mailing address. |
| stprma | The state or province of the registrant’s mailing address, if field countryma is US or CA. |
| cityma | The city of the registrant's mailing address. |
| zipma | The zip code of the registrant’s mailing address. |
| mas1 | The first line of the street of the registrant’s mailing address. |
| mas2 | The second line of the street of the registrant’s mailing address. |
| countryinc | The ISO 3166-1 country of incorporation for the registrant. |
| stprinc | The state or province of incorporation for the registrant, if countryinc is US or CA. |
| ein | Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States. |
| former | Most recent former name of the registrant, if any. |
| changed | Date of change from the former name, if any. |
| afs | Filer status with the SEC at the time of submission: 1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned. |
| wksi | Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement. |
| fye | Fiscal Year End Date, rounded to nearest month-end. |
| form | The submission type of the registrant’s filing. |
| period | Balance Sheet Date, rounded to nearest month-end. |
| fy | Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8). |
| fp | Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year. |
| filed | The date of the registrant’s filing with the Commission. |
| accepted | The acceptance date and time of the registrant’s filing with the Commission. |
| prevrpt | Previous Report – TRUE indicates that the submission information was subsequently amended. |
| detail | TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount). |
| instance | The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol. |
| nciks | Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing. |
| aciks | Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information. |
| adsh | ddate | tag | value | uom | qtrs | version | segments | coreg | footnote |
|---|---|---|---|---|---|---|---|---|---|
| 0001396814-25-000061 | 20250331 | Accrued Liabilities Current | 80069000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Accumulated Other Comprehensive Income Loss Net Of Tax | 343000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Acquisition Related Charges Impairment And Other | 6187000.0000 | USD | 1 | 0001396814-25-000061 | |||
| 0001396814-25-000061 | 20241231 | Additional Paid In Capital | 1009435000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 13151000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001396814-25-000061 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 14553000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | -3800000.0000 | USD | 1 | us-gaap/2024 | Business Acquisition= Flexion; | ||
| 0001396814-25-000061 | 20240331 | Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | -3806000.0000 | USD | 1 | us-gaap/2024 | Business Acquisition= Flexion Therapeutics Inc; | ||
| 0001396814-25-000061 | 20250331 | Capital Expenditures Incurred But Not Yet Paid | 767000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20231231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 153298000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Common Stock Shares Authorized | 250000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Common Stock Shares Outstanding | 46517000.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001396814-25-000061 | 20241231 | Common Stock Shares Outstanding | 47078000.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001396814-25-000061 | 20250331 | Common Stock Shares Outstanding | 46283407.0000 | shares | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Comprehensive Income Net Of Tax | 5820000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Convertible Debt Current | 201776000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Cost Of Revenue | 34306000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Costs And Expenses | 153905000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Earnings Per Share Basic | 0.1900 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Earnings Per Share Diluted | 0.1000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Income Taxes Paid Net | 286000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Increase Decrease In Other Operating Liabilities | -771000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | -897000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Interest Paid Net | 3969000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Inventory Net | 125282000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Net Cash Provided By Used In Investing Activities | -25629000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Net Income Loss | 8979000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001396814-25-000061 | 20241231 | Other Liabilities Noncurrent | 16817000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Payments To Acquire Businesses Net Of Cash Acquired | 0.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Preferred Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Preferred Stock Value | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Prepaid Expense And Other Assets Current | 21929000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Provision For Other Losses | 73000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 167117000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 2525000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Bupivacaine Liposome Injectable Suspension; | ||
| 0001396814-25-000061 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 168923000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 1329000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Royalty; | ||
| 0001396814-25-000061 | 20240331 | Selling General And Administrative Expense | 72026000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20231231 | Stockholders Equity | 870130000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Stockholders Equity | -97817000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001396814-25-000061 | 20250331 | Stockholders Equity | -201544000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001396814-25-000061 | 20250331 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 1000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Treasury Stock Common Value | 25121000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Accounts Payable Current | 19133000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Common Stock Value | 47000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 13151000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Amortization Of Financing Costs | 845000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 184052000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0001396814-25-000061 | 20250331 | Contingent Consideration Noncurrent | 17566000.0000 | USD | 0 | 0001396814-25-000061 | |||
| 0001396814-25-000061 | 20250331 | Convertible Debt Noncurrent | 279801000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Deferred Income Tax Expense Benefit | 1397000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Earnings Per Share Diluted | 0.1900 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20231231 | Goodwill | 163243000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Goodwill | 21520000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Increase Decrease In Inventories | -7572000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Increase Decrease In Prepaid Deferred Expense And Other Assets | 7111000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Intangible Assets Net Excluding Goodwill | 425970000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Liabilities | 775168000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Liabilities | 788128000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Liabilities And Stockholders Equity | 1586669000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Net Income Loss | 4812000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001396814-25-000061 | 20250331 | Operating Lease Liability Noncurrent | 43678000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Operating Lease Right Of Use Asset | 49222000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Payments To Acquire Businesses Net Of Cash Acquired | 16702000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Preferred Stock Shares Authorized | 5000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Preferred Stock Shares Outstanding | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 167594000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Product; | ||
| 0001396814-25-000061 | 20250331 | Secured Long Term Debt | 101489000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20231231 | Stockholders Equity | 247000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001396814-25-000061 | 20240331 | Stockholders Equity | 16000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Net Unrealized Investment Gain Loss; | ||
| 0001396814-25-000061 | 20241231 | Stockholders Equity | 190000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Net Unrealized Investment Gain Loss; | ||
| 0001396814-25-000061 | 20241231 | Stockholders Equity | 47000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001396814-25-000061 | 20250331 | Stockholders Equity | 104000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Net Unrealized Investment Gain Loss; | ||
| 0001396814-25-000061 | 20240331 | Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures | 36000.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001396814-25-000061 | 20240331 | Weighted Average Number Of Diluted Shares Outstanding | 52193000.0000 | shares | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Accumulated Other Comprehensive Income Loss Net Of Tax | 1351000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Adjustments Related To Tax Withholding For Share Based Compensation | 4000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001396814-25-000061 | 20250331 | Amortization Of Intangible Assets | 14322000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001396814-25-000061 | 20250331 | Assets | 1586669000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | -2675000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 283610000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | 30754000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Commitments And Contingencies | USD | 0 | us-gaap/2024 | ||||
| 0001396814-25-000061 | 20231231 | Common Stock Shares Outstanding | 46481000.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001396814-25-000061 | 20250331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | 8706000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Interest Expense Nonoperating | 3316000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Inventory Net | 133754000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Liabilities Current | 314732000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Operating Lease Right Of Use Asset | 48728000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Other Nonoperating Income Expense | -159000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Prepaid Expense And Other Assets Current | 27837000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Proceeds From Sale Of Short Term Investments | 69250000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Repayments Of Secured Debt | 2813000.0000 | USD | 1 | us-gaap/2024 | Debt Instrument= Term Loan A Facility; | ||
| 0001396814-25-000061 | 20241231 | Retained Earnings Accumulated Deficit | -206356000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 165824000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Product; | ||
| 0001396814-25-000061 | 20250331 | Selling General And Administrative Expense | 86776000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Share Based Compensation | 13151000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001396814-25-000061 | 20250331 | Shares Paid For Tax Withholding For Share Based Compensation | 10000.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001396814-25-000061 | 20241231 | Treasury Stock Common Shares | 837240.0000 | shares | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Accounts Payable Current | 23172000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Amortization Of Debt Discount Premium | 24000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Amortization Of Intangible Assets | 14322000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Assets Current | 745130000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | -2700000.0000 | USD | 1 | us-gaap/2024 | Business Acquisition= Flexion; | ||
| 0001396814-25-000061 | 20241231 | Cash And Cash Equivalents At Carrying Value | 276774000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Convertible Debt Current | 202086000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Cost Of Revenue | 47416000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Deferred Income Tax Liabilities Net | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Deferred Income Tax Liabilities Net | 6996000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Increase Decrease In Accounts Receivable | -3917000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Increase Decrease In Other Operating Liabilities | 1082000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Interest Paid Net | 2715000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Net Cash Provided By Used In Operating Activities | 35459000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Nonoperating Income Expense | 6716000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Operating Lease Liability Current | 8887000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Operating Lease Liability Current | 9405000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Payments To Acquire Property Plant And Equipment | 8548000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Property Plant And Equipment Net | 51100000.0000 | USD | 0 | us-gaap/2024 | Geographical= Non Us; Property Plant And Equipment By Type= Leasehold Improvements; | ||
| 0001396814-25-000061 | 20250331 | Property Plant And Equipment Net | 164451000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Research And Development Expense | 18238000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 2604000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Bupivacaine Liposome Injectable Suspension; | ||
| 0001396814-25-000061 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 5123000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Iovera; | ||
| 0001396814-25-000061 | 20241231 | Secured Long Term Debt | 104211000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Stockholders Equity | 136000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Translation Adjustment; | ||
| 0001396814-25-000061 | 20240331 | Stockholders Equity | 47000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001396814-25-000061 | 20241231 | Stockholders Equity | -25121000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0001396814-25-000061 | 20240331 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 1000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001396814-25-000061 | 20241231 | Treasury Stock Common Shares | 837000.0000 | shares | 0 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0001396814-25-000061 | 20250331 | Treasury Stock Common Shares | 837240.0000 | shares | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Weighted Average Number Of Diluted Shares Outstanding | 46526000.0000 | shares | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Amortization Of Financing Costs | 681000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Accounts Receivable Net Current | 104745000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Accrued Liabilities Current | 80124000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Acquisition Related Charges Impairment And Other | 1903000.0000 | USD | 1 | 0001396814-25-000061 | |||
| 0001396814-25-000061 | 20250331 | Adjustments Related To Tax Withholding For Share Based Compensation | 181000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Adjustments Related To Tax Withholding For Share Based Compensation | 181000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001396814-25-000061 | 20250331 | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 14553000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001396814-25-000061 | 20240331 | Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | -3806000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001396814-25-000061 | 20240331 | Comprehensive Income Net Of Tax | 8884000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Income Tax Expense Benefit | 4661000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Increase Decrease In Accounts Receivable | -8559000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Increase Decrease In Accrued Liabilities | 3471000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Net Cash Provided By Used In Financing Activities | -2817000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Net Cash Provided By Used In Operating Activities | 49101000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Net Income Loss | 8979000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Nonoperating Income Expense | 428000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Operating Income Loss | 13212000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Operating Lease Liability Noncurrent | 44645000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | -95000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | 1008000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | -86000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Preferred Stock Value | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Property Plant And Equipment Net | 167169000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 132430000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= E X P A R E L; | ||
| 0001396814-25-000061 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 1293000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Royalty; | ||
| 0001396814-25-000061 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 23338000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Z I L R E T T A; | ||
| 0001396814-25-000061 | 20250331 | Short Term Investments | 210016000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20231231 | Stockholders Equity | 123000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Translation Adjustment; | ||
| 0001396814-25-000061 | 20231231 | Stockholders Equity | 46000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001396814-25-000061 | 20240331 | Stockholders Equity | 152000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001396814-25-000061 | 20240331 | Stockholders Equity | 989780000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001396814-25-000061 | 20241231 | Stockholders Equity | 343000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001396814-25-000061 | 20241231 | Stockholders Equity | 153000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Translation Adjustment; | ||
| 0001396814-25-000061 | 20240331 | Amortization Of Intangible Assets | 14322000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001396814-25-000061 | 20241231 | Assets | 1553516000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 276774000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Common Stock Shares Issued | 47077844.0000 | shares | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Common Stock Value | 47000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Contingent Consideration Noncurrent | 20241000.0000 | USD | 0 | 0001396814-25-000061 | |||
| 0001396814-25-000061 | 20250331 | Deferred Income Tax Assets Net | 129008000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Depreciation Depletion And Amortization | 21168000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Earnings Per Share Basic | 0.1000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Equity Method Investments And Other Assets | 28031000.0000 | USD | 0 | 0001396814-25-000061 | |||
| 0001396814-25-000061 | 20241231 | Goodwill | 0.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | 13640000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Income Taxes Paid Net | -245000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Income Tax Expense Benefit | 3894000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Increase Decrease In Accounts Payable | -6976000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Investment Income Interest | 3903000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Liabilities Current | 309920000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Net Cash Provided By Used In Investing Activities | -15530000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Operating Income Loss | 1990000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | 1094000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Other Liabilities Noncurrent | 23866000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Payments To Acquire Property Plant And Equipment | 2836000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Payments To Acquire Short Term Investments | 69629000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Preferred Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Preferred Stock Shares Authorized | 5000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Preferred Stock Shares Outstanding | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Repayments Of Secured Debt | 2813000.0000 | USD | 1 | us-gaap/2024 | Debt Instrument= Term Loan A Facility; | ||
| 0001396814-25-000061 | 20250331 | Research And Development Expense | 25342000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Retained Earnings Accumulated Deficit | -201544000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 167117000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001396814-25-000061 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 168923000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001396814-25-000061 | 20250331 | Share Based Compensation | 14553000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20231231 | Stockholders Equity | 976633000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001396814-25-000061 | 20231231 | Stockholders Equity | -106796000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001396814-25-000061 | 20241231 | Stockholders Equity | -206356000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Retained Earnings; | ||
| 0001396814-25-000061 | 20250331 | Stockholders Equity | 798541000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Stockholders Equity | 1023808000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001396814-25-000061 | 20250331 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 1000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001396814-25-000061 | 20250331 | Costs And Expenses | 166933000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Adjustments Related To Tax Withholding For Share Based Compensation | 4000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Assets Current | 759962000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | -3806000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | -2675000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001396814-25-000061 | 20250331 | Cash And Cash Equivalents At Carrying Value | 283610000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Common Stock Shares Authorized | 250000000.0000 | shares | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Depreciation Depletion And Amortization | 18426000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250228 | Goodwill | 20763000.0000 | USD | 0 | us-gaap/2024 | Business Acquisition= G Q Bio Acquisition; | ||
| 0001396814-25-000061 | 20250331 | Increase Decrease In Accrued Liabilities | 4702000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Intangible Assets Net Excluding Goodwill | 434969000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Intangible Assets Net Excluding Goodwill | 58187000.0000 | USD | 0 | us-gaap/2024 | Finite Lived Intangible Assets By Major Class= In Process Research And Development; | ||
| 0001396814-25-000061 | 20250331 | Interest Expense Nonoperating | 4580000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Investment Income Interest | 6895000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Net Cash Provided By Used In Financing Activities | -2994000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | 13000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | -86000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Net Unrealized Investment Gain Loss; | ||
| 0001396814-25-000061 | 20250331 | Other Nonoperating Income Expense | 4401000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Payments To Acquire Short Term Investments | 56055000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Proceeds From Sale Of Short Term Investments | 43361000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 5030000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Iovera; | ||
| 0001396814-25-000061 | 20240331 | Revenue From Contract With Customer Excluding Assessed Tax | 25839000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= Z I L R E T T A; | ||
| 0001396814-25-000061 | 20250331 | Revenue From Contract With Customer Excluding Assessed Tax | 136529000.0000 | USD | 1 | us-gaap/2024 | Product Or Service= E X P A R E L; | ||
| 0001396814-25-000061 | 20240331 | Share Based Compensation | 13151000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Short Term Investments | 207841000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20231231 | Stockholders Equity | 124000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Net Unrealized Investment Gain Loss; | ||
| 0001396814-25-000061 | 20240331 | Stockholders Equity | 892162000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Stockholders Equity | 778348000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Stockholders Equity | 1351000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001396814-25-000061 | 20250331 | Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures | 53000.0000 | shares | 1 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001396814-25-000061 | 20250331 | Treasury Stock Common Shares | 837000.0000 | shares | 0 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0001396814-25-000061 | 20241231 | Treasury Stock Common Value | 25121000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Weighted Average Number Of Shares Outstanding Basic | 46499000.0000 | shares | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Liabilities And Stockholders Equity | 1553516000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Net Income Loss | 4812000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Increase Decrease In Inventories | 8472000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Accounts Receivable Net Current | 113304000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Additional Paid In Capital | 1023808000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Amortization Of Debt Discount Premium | 22000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Amortization Of Intangible Assets | 14322000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | -2675000.0000 | USD | 1 | us-gaap/2024 | Business Acquisition= Flexion Therapeutics Inc; | ||
| 0001396814-25-000061 | 20240331 | Capital Expenditures Incurred But Not Yet Paid | 607000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | 6836000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Common Stock Par Or Stated Value Per Share | 0.0010 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Common Stock Shares Issued | 47120647.0000 | shares | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Common Stock Shares Outstanding | 46240604.0000 | shares | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Common Stock Shares Outstanding | 47121000.0000 | shares | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001396814-25-000061 | 20241231 | Convertible Debt Noncurrent | 279334000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Deferred Income Tax Assets Net | 130376000.0000 | USD | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Deferred Income Tax Expense Benefit | 3463000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Equity Method Investments And Other Assets | 35649000.0000 | USD | 0 | 0001396814-25-000061 | |||
| 0001396814-25-000061 | 20250331 | Increase Decrease In Accounts Payable | 2464000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | -108000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Net Unrealized Investment Gain Loss; | ||
| 0001396814-25-000061 | 20240331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | -95000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001396814-25-000061 | 20250331 | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | 1008000.0000 | USD | 1 | us-gaap/2024 | Equity Components= Accumulated Other Comprehensive Income; | ||
| 0001396814-25-000061 | 20240331 | Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | -108000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20240331 | Payments Related To Tax Withholding For Share Based Compensation | 4000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Payments Related To Tax Withholding For Share Based Compensation | 181000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20241231 | Preferred Stock Shares Issued | 0.0000 | shares | 0 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Property Plant And Equipment Net | 50000000.0000 | USD | 0 | us-gaap/2024 | Geographical= Non Us; Property Plant And Equipment By Type= Leasehold Improvements; | ||
| 0001396814-25-000061 | 20250331 | Provision For Other Losses | -5887000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Share Based Compensation | 14553000.0000 | USD | 1 | us-gaap/2024 | Business Segments= Reportable Segment; | ||
| 0001396814-25-000061 | 20241231 | Stockholders Equity | 1009435000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Additional Paid In Capital; | ||
| 0001396814-25-000061 | 20250331 | Stockholders Equity | 1247000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Accumulated Translation Adjustment; | ||
| 0001396814-25-000061 | 20250331 | Stockholders Equity | 47000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Common Stock; | ||
| 0001396814-25-000061 | 20250331 | Stockholders Equity | -25121000.0000 | USD | 0 | us-gaap/2024 | Equity Components= Treasury Stock Common; | ||
| 0001396814-25-000061 | 20240331 | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | 1000.0000 | USD | 1 | us-gaap/2024 | |||
| 0001396814-25-000061 | 20250331 | Weighted Average Number Of Shares Outstanding Basic | 46275000.0000 | shares | 1 | us-gaap/2024 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| ddate | The end date for the data value, rounded to the nearest month end. |
| qtrs | The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value. |
| uom | The unit of measure for the value. |
| segments | Tags used to represent axis and member reporting. |
| coreg | If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity. |
| value | The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point. |
| footnote | The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank. |
| tag | version | custom | abstract | datatype | iord | crdr | tlabel | doc |
|---|---|---|---|---|---|---|---|---|
| Increase Decrease In Accounts Receivable | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Accounts Receivable | The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. |
| Amortization Of Debt Discount Premium | us-gaap/2024 | 0 | 0 | monetary | D | D | Amortization of Debt Discount (Premium) | Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. |
| Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets, Current | Amount of asset recognized for present right to economic benefit, classified as current. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents | Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Operating Lease Liability Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Current | Present value of lessee's discounted obligation for lease payments from operating lease, classified as current. |
| Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Revenue from Contract with Customer, Excluding Assessed Tax | Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. |
| Deferred Income Tax Assets Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Deferred Income Tax Assets, Net | Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting. |
| Payments To Acquire Businesses Net Of Cash Acquired | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Businesses, Net of Cash Acquired | The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. |
| Payments To Acquire Property Plant And Equipment | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Property, Plant, and Equipment | The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. |
| Secured Long Term Debt | us-gaap/2024 | 0 | 0 | monetary | I | C | Secured Long-Term Debt, Noncurrent | Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets. |
| Comprehensive Income Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2024 | 0 | 0 | monetary | D | C | Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. |
| Liabilities | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities | Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. |
| Liabilities And Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities and Equity | Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. |
| Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | D | C | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax | Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. |
| Retained Earnings Accumulated Deficit | us-gaap/2024 | 0 | 0 | monetary | I | C | Retained Earnings (Accumulated Deficit) | Amount of accumulated undistributed earnings (deficit). |
| Short Term Investments | us-gaap/2024 | 0 | 0 | monetary | I | D | Short-Term Investments | Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current. |
| Accrued Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accrued Liabilities, Current | Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Accounts Receivable Net Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Accounts Receivable, after Allowance for Credit Loss, Current | Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. |
| Additional Paid In Capital | us-gaap/2024 | 0 | 0 | monetary | I | C | Additional Paid in Capital | Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. |
| Adjustments Related To Tax Withholding For Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation | Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement. |
| Common Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Common Stock, Par or Stated Value Per Share | Face amount or stated value per share of common stock. | |
| Common Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Outstanding | Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. | |
| Convertible Debt Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Convertible Debt, Current | The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. |
| Income Tax Expense Benefit | us-gaap/2024 | 0 | 0 | monetary | D | D | Income Tax Expense (Benefit) | Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. |
| Net Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Net Income (Loss) Attributable to Parent | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. |
| Stockholders Equity | us-gaap/2024 | 0 | 0 | monetary | I | C | Equity, Attributable to Parent | Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. |
| Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | us-gaap/2024 | 0 | 0 | monetary | D | C | Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures | Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. |
| Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Diluted | The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | 0 | 0 | monetary | I | C | Accumulated Other Comprehensive Income (Loss), Net of Tax | Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. |
| Assets | us-gaap/2024 | 0 | 0 | monetary | I | D | Assets | Amount of asset recognized for present right to economic benefit. |
| Common Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares, Issued | Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. | |
| Earnings Per Share Diluted | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Diluted | The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. | |
| Operating Lease Right Of Use Asset | us-gaap/2024 | 0 | 0 | monetary | I | D | Operating Lease, Right-of-Use Asset | Amount of lessee's right to use underlying asset under operating lease. |
| Convertible Debt Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Convertible Debt, Noncurrent | Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock. |
| Cost Of Revenue | us-gaap/2024 | 0 | 0 | monetary | D | D | Cost of Revenue | The aggregate cost of goods produced and sold and services rendered during the reporting period. |
| Depreciation Depletion And Amortization | us-gaap/2024 | 0 | 0 | monetary | D | D | Depreciation, Depletion and Amortization | The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. |
| Interest Expense Nonoperating | us-gaap/2024 | 0 | 0 | monetary | D | D | Interest Expense, Nonoperating | Amount of interest expense classified as nonoperating. |
| Liabilities Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Liabilities, Current | Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. |
| Preferred Stock Shares Issued | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Issued | Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. | |
| Selling General And Administrative Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Selling, General and Administrative Expense | The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. |
| Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | D | Share-Based Payment Arrangement, Noncash Expense | Amount of noncash expense for share-based payment arrangement. |
| Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures | us-gaap/2024 | 0 | 0 | shares | D | Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures | Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. | |
| Goodwill | us-gaap/2024 | 0 | 0 | monetary | I | D | Goodwill | Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. |
| Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Cash and Cash Equivalents, at Carrying Value | Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. |
| Income Taxes Paid Net | us-gaap/2024 | 0 | 0 | monetary | D | C | Income Taxes Paid, Net | Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. |
| Increase Decrease In Inventories | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Inventories | The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. |
| Increase Decrease In Other Operating Liabilities | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Other Operating Liabilities | Amount of increase (decrease) in operating liabilities classified as other. |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | 0 | 0 | monetary | D | C | Increase (Decrease) in Prepaid Expense and Other Assets | Amount of increase (decrease) in prepaid expenses, and assets classified as other. |
| Nonoperating Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Nonoperating Income (Expense) | The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). |
| Preferred Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Preferred Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Proceeds From Sale Of Short Term Investments | us-gaap/2024 | 0 | 0 | monetary | D | D | Proceeds from Sale of Short-Term Investments | The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. |
| Repayments Of Secured Debt | us-gaap/2024 | 0 | 0 | monetary | D | C | Repayments of Secured Debt | The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt. |
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | us-gaap/2024 | 0 | 0 | monetary | D | D | Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability | Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. |
| Costs And Expenses | us-gaap/2024 | 0 | 0 | monetary | D | D | Costs and Expenses | Total costs of sales and operating expenses for the period. |
| Deferred Income Tax Expense Benefit | us-gaap/2024 | 0 | 0 | monetary | D | D | Deferred Income Tax Expense (Benefit) | Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. |
| Intangible Assets Net Excluding Goodwill | us-gaap/2024 | 0 | 0 | monetary | I | D | Intangible Assets, Net (Excluding Goodwill) | Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. |
| Net Cash Provided By Used In Operating Activities | us-gaap/2024 | 0 | 0 | monetary | D | Net Cash Provided by (Used in) Operating Activities | Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. | |
| Operating Income Loss | us-gaap/2024 | 0 | 0 | monetary | D | C | Operating Income (Loss) | The net result for the period of deducting operating expenses from operating revenues. |
| Other Liabilities Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Other Liabilities, Noncurrent | Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer. |
| Prepaid Expense And Other Assets Current | us-gaap/2024 | 0 | 0 | monetary | I | D | Prepaid Expense and Other Assets, Current | Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. |
| Amortization Of Financing Costs | us-gaap/2024 | 0 | 0 | monetary | D | D | Amortization of Debt Issuance Costs | Amount of amortization expense attributable to debt issuance costs. |
| Capital Expenditures Incurred But Not Yet Paid | us-gaap/2024 | 0 | 0 | monetary | D | C | Capital Expenditures Incurred but Not yet Paid | Future cash outflow to pay for purchases of fixed assets that have occurred. |
| Common Stock Value | us-gaap/2024 | 0 | 0 | monetary | I | C | Common Stock, Value, Issued | Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. |
| Inventory Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Inventory, Net | Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. |
| Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | Amount after tax of other comprehensive income (loss) attributable to parent entity. |
| Provision For Other Losses | us-gaap/2024 | 0 | 0 | monetary | D | D | Provision for Other Losses | Amount of expense related to other loss. |
| Research And Development Expense | us-gaap/2024 | 0 | 0 | monetary | D | D | Research and Development Expense | Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. |
| Contingent Consideration Noncurrent | 0001396814-25-000061 | 1 | 0 | monetary | I | C | Contingent Consideration, Noncurrent | Contingent Consideration, Noncurrent |
| Equity Method Investments And Other Assets | 0001396814-25-000061 | 1 | 0 | monetary | I | D | Equity Method Investments and Other Assets | Equity Method Investments and Other Assets |
| Accounts Payable Current | us-gaap/2024 | 0 | 0 | monetary | I | C | Accounts Payable, Current | Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). |
| Amortization Of Intangible Assets | us-gaap/2024 | 0 | 0 | monetary | D | D | Amortization of Intangible Assets | The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | 0 | 0 | monetary | D | D | Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. |
| Commitments And Contingencies | us-gaap/2024 | 0 | 0 | monetary | I | C | Commitments and Contingencies | Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. |
| Common Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Common Stock, Shares Authorized | The maximum number of common shares permitted to be issued by an entity's charter and bylaws. | |
| Deferred Income Tax Liabilities Net | us-gaap/2024 | 0 | 0 | monetary | I | C | Deferred Income Tax Liabilities, Net | Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. |
| Increase Decrease In Accounts Payable | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accounts Payable | The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. |
| Interest Paid Net | us-gaap/2024 | 0 | 0 | monetary | D | C | Interest Paid, Excluding Capitalized Interest, Operating Activities | Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. |
| Net Cash Provided By Used In Financing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Financing Activities | Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. |
| Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent | Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity. |
| Payments Related To Tax Withholding For Share Based Compensation | us-gaap/2024 | 0 | 0 | monetary | D | C | Payment, Tax Withholding, Share-Based Payment Arrangement | Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. |
| Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | 0 | 0 | perShare | I | Preferred Stock, Par or Stated Value Per Share | Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. | |
| Shares Paid For Tax Withholding For Share Based Compensation | us-gaap/2024 | 0 | 0 | shares | D | Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation | Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement. | |
| Acquisition Related Charges Impairment And Other | 0001396814-25-000061 | 1 | 0 | monetary | D | D | Acquisition-Related Charges, Impairment And Other | Acquisition-Related Charges, Impairment And Other |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | 0 | 0 | monetary | D | C | APIC, Share-Based Payment Arrangement, Increase for Cost Recognition | Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. |
| Earnings Per Share Basic | us-gaap/2024 | 0 | 0 | perShare | D | Earnings Per Share, Basic | The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. | |
| Investment Income Interest | us-gaap/2024 | 0 | 0 | monetary | D | C | Investment Income, Interest | Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. |
| Net Cash Provided By Used In Investing Activities | us-gaap/2024 | 0 | 0 | monetary | D | D | Net Cash Provided by (Used in) Investing Activities | Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. |
| Other Nonoperating Income Expense | us-gaap/2024 | 0 | 0 | monetary | D | C | Other Nonoperating Income (Expense) | Amount of income (expense) related to nonoperating activities, classified as other. |
| Preferred Stock Shares Authorized | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Authorized | The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. | |
| Preferred Stock Shares Outstanding | us-gaap/2024 | 0 | 0 | shares | I | Preferred Stock, Shares Outstanding | Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. | |
| Treasury Stock Common Value | us-gaap/2024 | 0 | 0 | monetary | I | D | Treasury Stock, Common, Value | Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury. |
| Increase Decrease In Accrued Liabilities | us-gaap/2024 | 0 | 0 | monetary | D | D | Increase (Decrease) in Accrued Liabilities | The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. |
| Operating Lease Liability Noncurrent | us-gaap/2024 | 0 | 0 | monetary | I | C | Operating Lease, Liability, Noncurrent | Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. |
| Payments To Acquire Short Term Investments | us-gaap/2024 | 0 | 0 | monetary | D | C | Payments to Acquire Short-Term Investments | The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. |
| Property Plant And Equipment Net | us-gaap/2024 | 0 | 0 | monetary | I | D | Property, Plant and Equipment, Net | Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. |
| Treasury Stock Common Shares | us-gaap/2024 | 0 | 0 | shares | I | Treasury Stock, Common, Shares | Number of previously issued common shares repurchased by the issuing entity and held in treasury. | |
| Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | 0 | 0 | shares | D | Weighted Average Number of Shares Outstanding, Basic | Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. |
| Field Name | Field Description |
|---|---|
| tag | The unique identifier (name) for a tag in a specific taxonomy release. |
| version | For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined. |
| custom | 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns. |
| abstract | 1 if the tag is not used to represent a numeric fact. |
| datatype | If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag. |
| iord | If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration. |
| crdr | If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL. |
| tlabel | If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here. |
| doc | The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL. |
| adsh | report | line | stmt | inpth | rfile | tag | version | plabel | negating |
|---|---|---|---|---|---|---|---|---|---|
| 0001396814-25-000061 | 2 | 3 | BS | 0 | H | Cash And Cash Equivalents At Carrying Value | us-gaap/2024 | Cash and cash equivalents | 0 |
| 0001396814-25-000061 | 2 | 4 | BS | 0 | H | Short Term Investments | us-gaap/2024 | Short-term available-for-sale investments | 0 |
| 0001396814-25-000061 | 2 | 5 | BS | 0 | H | Accounts Receivable Net Current | us-gaap/2024 | Accounts receivable, net | 0 |
| 0001396814-25-000061 | 2 | 6 | BS | 0 | H | Inventory Net | us-gaap/2024 | Inventories, net | 0 |
| 0001396814-25-000061 | 2 | 7 | BS | 0 | H | Prepaid Expense And Other Assets Current | us-gaap/2024 | Prepaid expenses and other current assets | 0 |
| 0001396814-25-000061 | 2 | 8 | BS | 0 | H | Assets Current | us-gaap/2024 | Total current assets | 0 |
| 0001396814-25-000061 | 2 | 9 | BS | 0 | H | Property Plant And Equipment Net | us-gaap/2024 | Fixed assets, net | 0 |
| 0001396814-25-000061 | 2 | 10 | BS | 0 | H | Operating Lease Right Of Use Asset | us-gaap/2024 | Right-of-use assets, net | 0 |
| 0001396814-25-000061 | 2 | 11 | BS | 0 | H | Goodwill | us-gaap/2024 | Goodwill | 0 |
| 0001396814-25-000061 | 2 | 12 | BS | 0 | H | Intangible Assets Net Excluding Goodwill | us-gaap/2024 | Intangible assets, net | 0 |
| 0001396814-25-000061 | 2 | 13 | BS | 0 | H | Deferred Income Tax Assets Net | us-gaap/2024 | Deferred tax assets | 0 |
| 0001396814-25-000061 | 2 | 14 | BS | 0 | H | Equity Method Investments And Other Assets | 0001396814-25-000061 | Investments and other assets | 0 |
| 0001396814-25-000061 | 2 | 15 | BS | 0 | H | Assets | us-gaap/2024 | Total assets | 0 |
| 0001396814-25-000061 | 2 | 18 | BS | 0 | H | Accounts Payable Current | us-gaap/2024 | Accounts payable | 0 |
| 0001396814-25-000061 | 2 | 19 | BS | 0 | H | Accrued Liabilities Current | us-gaap/2024 | Accrued expenses | 0 |
| 0001396814-25-000061 | 2 | 20 | BS | 0 | H | Operating Lease Liability Current | us-gaap/2024 | Lease liabilities | 0 |
| 0001396814-25-000061 | 2 | 21 | BS | 0 | H | Convertible Debt Current | us-gaap/2024 | Current portion of convertible senior notes, net | 0 |
| 0001396814-25-000061 | 2 | 22 | BS | 0 | H | Liabilities Current | us-gaap/2024 | Total current liabilities | 0 |
| 0001396814-25-000061 | 2 | 23 | BS | 0 | H | Convertible Debt Noncurrent | us-gaap/2024 | Convertible senior notes, net | 0 |
| 0001396814-25-000061 | 2 | 24 | BS | 0 | H | Secured Long Term Debt | us-gaap/2024 | Long-term debt, net | 0 |
| 0001396814-25-000061 | 2 | 25 | BS | 0 | H | Operating Lease Liability Noncurrent | us-gaap/2024 | Lease liabilities | 0 |
| 0001396814-25-000061 | 2 | 26 | BS | 0 | H | Contingent Consideration Noncurrent | 0001396814-25-000061 | Contingent consideration | 0 |
| 0001396814-25-000061 | 2 | 27 | BS | 0 | H | Deferred Income Tax Liabilities Net | us-gaap/2024 | Deferred tax liabilities | 0 |
| 0001396814-25-000061 | 2 | 28 | BS | 0 | H | Other Liabilities Noncurrent | us-gaap/2024 | Other liabilities | 0 |
| 0001396814-25-000061 | 2 | 29 | BS | 0 | H | Liabilities | us-gaap/2024 | Total liabilities | 0 |
| 0001396814-25-000061 | 2 | 30 | BS | 0 | H | Commitments And Contingencies | us-gaap/2024 | Commitments and contingencies (Note 16) | 0 |
| 0001396814-25-000061 | 2 | 32 | BS | 0 | H | Preferred Stock Value | us-gaap/2024 | Preferred stock, par value $0.001; 5,000,000 shares authorized; none issued and outstanding at March 31, 2025 and December 31, 2024 | 0 |
| 0001396814-25-000061 | 2 | 33 | BS | 0 | H | Common Stock Value | us-gaap/2024 | Common stock, par value $0.001; 250,000,000 shares authorized; 47,120,647 shares issued and 46,283,407 shares outstanding at March 31, 2025 and 47,077,844 shares issued and 46,240,604 shares outstanding at December 31, 2024 | 0 |
| 0001396814-25-000061 | 2 | 34 | BS | 0 | H | Treasury Stock Common Value | us-gaap/2024 | Treasury stock, at cost, 837,240 shares at March 31, 2025 and December 31, 2024, inclusive of excise tax | 1 |
| 0001396814-25-000061 | 2 | 35 | BS | 0 | H | Additional Paid In Capital | us-gaap/2024 | Additional paid-in capital | 0 |
| 0001396814-25-000061 | 2 | 36 | BS | 0 | H | Retained Earnings Accumulated Deficit | us-gaap/2024 | Accumulated deficit | 0 |
| 0001396814-25-000061 | 2 | 37 | BS | 0 | H | Accumulated Other Comprehensive Income Loss Net Of Tax | us-gaap/2024 | Accumulated other comprehensive income | 0 |
| 0001396814-25-000061 | 2 | 38 | BS | 0 | H | Stockholders Equity | us-gaap/2024 | Total stockholders equity | 0 |
| 0001396814-25-000061 | 2 | 39 | BS | 0 | H | Liabilities And Stockholders Equity | us-gaap/2024 | Total liabilities and stockholders equity | 0 |
| 0001396814-25-000061 | 3 | 1 | BS | 1 | H | Preferred Stock Par Or Stated Value Per Share | us-gaap/2024 | Preferred stock, par value (in dollars per share) | 0 |
| 0001396814-25-000061 | 3 | 2 | BS | 1 | H | Preferred Stock Shares Authorized | us-gaap/2024 | Preferred stock, shares authorized (in shares) | 0 |
| 0001396814-25-000061 | 3 | 3 | BS | 1 | H | Preferred Stock Shares Issued | us-gaap/2024 | Preferred stock, shares issued (in shares) | 0 |
| 0001396814-25-000061 | 3 | 4 | BS | 1 | H | Preferred Stock Shares Outstanding | us-gaap/2024 | Preferred stock, shares outstanding (in shares) | 0 |
| 0001396814-25-000061 | 3 | 5 | BS | 1 | H | Common Stock Par Or Stated Value Per Share | us-gaap/2024 | Common stock, par value (in dollars per share) | 0 |
| 0001396814-25-000061 | 3 | 6 | BS | 1 | H | Common Stock Shares Authorized | us-gaap/2024 | Common stock, shares authorized (in shares) | 0 |
| 0001396814-25-000061 | 3 | 7 | BS | 1 | H | Common Stock Shares Issued | us-gaap/2024 | Common stock, shares issued (in shares) | 0 |
| 0001396814-25-000061 | 3 | 8 | BS | 1 | H | Common Stock Shares Outstanding | us-gaap/2024 | Common stock, shares outstanding (in shares) | 0 |
| 0001396814-25-000061 | 3 | 9 | BS | 1 | H | Treasury Stock Common Shares | us-gaap/2024 | Treasury stock (in shares) | 0 |
| 0001396814-25-000061 | 4 | 8 | IS | 0 | H | Revenue From Contract With Customer Excluding Assessed Tax | us-gaap/2024 | Total revenues | 0 |
| 0001396814-25-000061 | 4 | 10 | IS | 0 | H | Cost Of Revenue | us-gaap/2024 | Cost of goods sold | 0 |
| 0001396814-25-000061 | 4 | 11 | IS | 0 | H | Research And Development Expense | us-gaap/2024 | Research and development | 0 |
| 0001396814-25-000061 | 4 | 12 | IS | 0 | H | Selling General And Administrative Expense | us-gaap/2024 | Selling, general and administrative | 0 |
| 0001396814-25-000061 | 4 | 13 | IS | 0 | H | Amortization Of Intangible Assets | us-gaap/2024 | Amortization of acquired intangible assets | 0 |
| 0001396814-25-000061 | 4 | 14 | IS | 0 | H | Acquisition Related Charges Impairment And Other | 0001396814-25-000061 | Contingent consideration gains, acquisition-related expenses, restructuring and other | 0 |
| 0001396814-25-000061 | 4 | 15 | IS | 0 | H | Costs And Expenses | us-gaap/2024 | Total operating expenses | 0 |
| 0001396814-25-000061 | 4 | 16 | IS | 0 | H | Operating Income Loss | us-gaap/2024 | Income from operations | 0 |
| 0001396814-25-000061 | 4 | 18 | IS | 0 | H | Investment Income Interest | us-gaap/2024 | Interest income | 0 |
| 0001396814-25-000061 | 4 | 19 | IS | 0 | H | Interest Expense Nonoperating | us-gaap/2024 | Interest expense | 1 |
| 0001396814-25-000061 | 4 | 20 | IS | 0 | H | Other Nonoperating Income Expense | us-gaap/2024 | Other, net | 0 |
| 0001396814-25-000061 | 4 | 21 | IS | 0 | H | Nonoperating Income Expense | us-gaap/2024 | Total other income, net | 0 |
| 0001396814-25-000061 | 4 | 22 | IS | 0 | H | Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | us-gaap/2024 | Income before income taxes | 0 |
| 0001396814-25-000061 | 4 | 23 | IS | 0 | H | Income Tax Expense Benefit | us-gaap/2024 | Income tax expense | 1 |
| 0001396814-25-000061 | 4 | 24 | IS | 0 | H | Net Income Loss | us-gaap/2024 | Net income | 0 |
| 0001396814-25-000061 | 4 | 26 | IS | 0 | H | Earnings Per Share Basic | us-gaap/2024 | Basic net (loss) income per common share (in dollars per share) | 0 |
| 0001396814-25-000061 | 4 | 27 | IS | 0 | H | Earnings Per Share Diluted | us-gaap/2024 | Diluted net (loss) income per common share (in dollars per share) | 0 |
| 0001396814-25-000061 | 4 | 29 | IS | 0 | H | Weighted Average Number Of Shares Outstanding Basic | us-gaap/2024 | Basic (in shares) | 0 |
| 0001396814-25-000061 | 4 | 30 | IS | 0 | H | Weighted Average Number Of Diluted Shares Outstanding | us-gaap/2024 | Diluted (in shares) | 0 |
| 0001396814-25-000061 | 5 | 1 | CI | 0 | H | Net Income Loss | us-gaap/2024 | Net income | 0 |
| 0001396814-25-000061 | 5 | 3 | CI | 0 | H | Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax | us-gaap/2024 | Net unrealized loss on investments, net of tax | 0 |
| 0001396814-25-000061 | 5 | 4 | CI | 0 | H | Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent | us-gaap/2024 | Foreign currency translation adjustments | 0 |
| 0001396814-25-000061 | 5 | 5 | CI | 0 | H | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | us-gaap/2024 | Total other comprehensive income (loss) | 0 |
| 0001396814-25-000061 | 5 | 6 | CI | 0 | H | Comprehensive Income Net Of Tax | us-gaap/2024 | Comprehensive income | 0 |
| 0001396814-25-000061 | 6 | 11 | EQ | 0 | H | Common Stock Shares Outstanding | us-gaap/2024 | Beginning balance (in shares) | 0 |
| 0001396814-25-000061 | 6 | 12 | EQ | 0 | H | Treasury Stock Common Shares | us-gaap/2024 | Treasury Shares, Beginning balance (in shares) | 1 |
| 0001396814-25-000061 | 6 | 13 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Balance at beginning of period | 0 |
| 0001396814-25-000061 | 6 | 14 | EQ | 0 | H | Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures | us-gaap/2024 | Vested restricted stock units (in shares) | 0 |
| 0001396814-25-000061 | 6 | 15 | EQ | 0 | H | Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures | us-gaap/2024 | Vested restricted stock units | 0 |
| 0001396814-25-000061 | 6 | 16 | EQ | 0 | H | Shares Paid For Tax Withholding For Share Based Compensation | us-gaap/2024 | Common stock withheld for employee withholding tax liabilities on vested restricted stock units (in shares) | 1 |
| 0001396814-25-000061 | 6 | 17 | EQ | 0 | H | Adjustments Related To Tax Withholding For Share Based Compensation | us-gaap/2024 | Common stock withheld for employee withholding tax liabilities on vested restricted stock units | 1 |
| 0001396814-25-000061 | 6 | 18 | EQ | 0 | H | Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | us-gaap/2024 | Stock-based compensation | 0 |
| 0001396814-25-000061 | 6 | 19 | EQ | 0 | H | Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent | us-gaap/2024 | Other comprehensive income (loss) | 0 |
| 0001396814-25-000061 | 6 | 20 | EQ | 0 | H | Net Income Loss | us-gaap/2024 | Net income | 0 |
| 0001396814-25-000061 | 6 | 21 | EQ | 0 | H | Common Stock Shares Outstanding | us-gaap/2024 | Ending balance (in shares) | 0 |
| 0001396814-25-000061 | 6 | 22 | EQ | 0 | H | Treasury Stock Common Shares | us-gaap/2024 | Treasury Shares, Ending balance (in shares) | 1 |
| 0001396814-25-000061 | 6 | 23 | EQ | 0 | H | Stockholders Equity | us-gaap/2024 | Balance at ending of period | 0 |
| 0001396814-25-000061 | 7 | 9 | CF | 0 | H | Net Income Loss | us-gaap/2024 | Net income | 0 |
| 0001396814-25-000061 | 7 | 11 | CF | 0 | H | Deferred Income Tax Expense Benefit | us-gaap/2024 | Deferred taxes | 0 |
| 0001396814-25-000061 | 7 | 12 | CF | 0 | H | Depreciation Depletion And Amortization | us-gaap/2024 | Depreciation of fixed assets and amortization of intangible assets | 0 |
| 0001396814-25-000061 | 7 | 13 | CF | 0 | H | Amortization Of Financing Costs | us-gaap/2024 | Amortization of debt issuance costs | 0 |
| 0001396814-25-000061 | 7 | 14 | CF | 0 | H | Amortization Of Debt Discount Premium | us-gaap/2024 | Amortization of debt discount | 0 |
| 0001396814-25-000061 | 7 | 15 | CF | 0 | H | Share Based Compensation | us-gaap/2024 | Stock-based compensation | 0 |
| 0001396814-25-000061 | 7 | 16 | CF | 0 | H | Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | us-gaap/2024 | Changes in contingent consideration | 0 |
| 0001396814-25-000061 | 7 | 17 | CF | 0 | H | Provision For Other Losses | us-gaap/2024 | Other net (gains) losses | 0 |
| 0001396814-25-000061 | 7 | 19 | CF | 0 | H | Increase Decrease In Accounts Receivable | us-gaap/2024 | Accounts receivable, net | 1 |
| 0001396814-25-000061 | 7 | 20 | CF | 0 | H | Increase Decrease In Inventories | us-gaap/2024 | Inventories, net | 1 |
| 0001396814-25-000061 | 7 | 21 | CF | 0 | H | Increase Decrease In Prepaid Deferred Expense And Other Assets | us-gaap/2024 | Prepaid expenses and other assets | 1 |
| 0001396814-25-000061 | 7 | 22 | CF | 0 | H | Increase Decrease In Accounts Payable | us-gaap/2024 | Accounts payable | 0 |
| 0001396814-25-000061 | 7 | 23 | CF | 0 | H | Increase Decrease In Accrued Liabilities | us-gaap/2024 | Accrued expenses and income taxes payable | 0 |
| 0001396814-25-000061 | 7 | 24 | CF | 0 | H | Increase Decrease In Other Operating Liabilities | us-gaap/2024 | Other liabilities | 0 |
| 0001396814-25-000061 | 7 | 25 | CF | 0 | H | Net Cash Provided By Used In Operating Activities | us-gaap/2024 | Net cash provided by operating activities | 0 |
| 0001396814-25-000061 | 7 | 27 | CF | 0 | H | Payments To Acquire Businesses Net Of Cash Acquired | us-gaap/2024 | Acquisition of GQ Bio Therapeutics GmbH (net of cash acquired) | 1 |
| 0001396814-25-000061 | 7 | 28 | CF | 0 | H | Payments To Acquire Property Plant And Equipment | us-gaap/2024 | Purchases of fixed assets | 1 |
| 0001396814-25-000061 | 7 | 29 | CF | 0 | H | Payments To Acquire Short Term Investments | us-gaap/2024 | Purchases of available-for-sale investments | 1 |
| 0001396814-25-000061 | 7 | 30 | CF | 0 | H | Proceeds From Sale Of Short Term Investments | us-gaap/2024 | Sales of available-for-sale investments | 0 |
| 0001396814-25-000061 | 7 | 31 | CF | 0 | H | Net Cash Provided By Used In Investing Activities | us-gaap/2024 | Net cash used in investing activities | 0 |
| 0001396814-25-000061 | 7 | 33 | CF | 0 | H | Payments Related To Tax Withholding For Share Based Compensation | us-gaap/2024 | Payment of employee withholding taxes on restricted stock unit vests | 1 |
| 0001396814-25-000061 | 7 | 34 | CF | 0 | H | Repayments Of Secured Debt | us-gaap/2024 | Repayment of Term loan facility | 1 |
| 0001396814-25-000061 | 7 | 35 | CF | 0 | H | Net Cash Provided By Used In Financing Activities | us-gaap/2024 | Net cash used in financing activities | 0 |
| 0001396814-25-000061 | 7 | 36 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | us-gaap/2024 | Net increase in cash and cash equivalents | 0 |
| 0001396814-25-000061 | 7 | 37 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash and cash equivalents, beginning of period | 0 |
| 0001396814-25-000061 | 7 | 38 | CF | 0 | H | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | us-gaap/2024 | Cash and cash equivalents, end of period | 0 |
| 0001396814-25-000061 | 7 | 40 | CF | 0 | H | Interest Paid Net | us-gaap/2024 | Cash paid for interest | 0 |
| 0001396814-25-000061 | 7 | 41 | CF | 0 | H | Income Taxes Paid Net | us-gaap/2024 | Net cash paid (received) for income taxes | 0 |
| 0001396814-25-000061 | 7 | 43 | CF | 0 | H | Capital Expenditures Incurred But Not Yet Paid | us-gaap/2024 | Fixed assets included in accounts payable and accrued liabilities | 0 |
| Field Name | Field Description |
|---|---|
| adsh | Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission. |
| report | Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site. |
| line | Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived. |
| stmt | The financial statement location to which the value of the “report” field pertains. |
| inpth | Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700. |
| rfile | The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file. |
| tag | The tag chosen by the filer for this line item. |
| version | The taxonomy identifier if the tag is a standard tag, otherwise adsh. |
| plabel | The text presented on the line item, also known as a “preferred” label. |
| negating | Flag to indicate whether the plabel is negating. |